Literature DB >> 16307311

Validated ligand mapping of ACE active site.

Daniel J Kuster1, Garland R Marshall.   

Abstract

Crystal structures of angiotensin-converting enzyme (ACE) complexed with three inhibitors (lisinopril, captopril, enalapril) provided experimental data for testing the validity of a prior active site model predicting the bound conformation of the inhibitors. The ACE active site model - predicted over 18 years ago using a series of potent ACE inhibitors of diverse chemical structure - was recreated using published data and commercial software. Comparison between the predicted structures of the three inhibitors bound to the active site of ACE and those determined experimentally yielded root mean square deviation (RMSD) values of 0.43-0.81 A, among the distances defining the active site map. The bound conformations of the chemically relevant atoms were accurately deduced from the geometry of ligands, applying the assumption that the geometry of the active site groups responsible for binding and catalysis of amide hydrolysis was constrained. The mapping of bound inhibitors at the ACE active site was validated for known experimental compounds, so that the constrained conformational search methodology may be applied with confidence when no experimentally determined structure of the enzyme yet exists, but potent, diverse inhibitors are available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307311     DOI: 10.1007/s10822-005-9017-z

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  13 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  The Cambridge Structural Database: a quarter of a million crystal structures and rising.

Authors:  Frank H Allen
Journal:  Acta Crystallogr B       Date:  2002-05-29

3.  Calibration of effective van der Waals atomic contact radii for proteins and peptides.

Authors:  H Iijima; J B Dunbar; G R Marshall
Journal:  Proteins       Date:  1987

4.  Analysis of zinc binding sites in protein crystal structures.

Authors:  I L Alberts; K Nadassy; S J Wodak
Journal:  Protein Sci       Date:  1998-08       Impact factor: 6.725

5.  The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.

Authors:  A Rousseau; A Michaud; M T Chauvet; M Lenfant; P Corvol
Journal:  J Biol Chem       Date:  1995-02-24       Impact factor: 5.157

6.  Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.

Authors:  E Jaspard; L Wei; F Alhenc-Gelas
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

8.  Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.

Authors:  Nathalie Lapointe; James N Tsoporis; Thomas G Parker; Charles Blais; Albert Adam; Dominique Rouleau; Graham Slaughter; Robert Clément; Christian E Deschepper; Jean L Rouleau
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

9.  Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.

Authors:  Ramanathan Natesh; Sylva L U Schwager; Hazel R Evans; Edward D Sturrock; K Ravi Acharya
Journal:  Biochemistry       Date:  2004-07-13       Impact factor: 3.162

10.  A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies.

Authors:  D Mayer; C B Naylor; I Motoc; G R Marshall
Journal:  J Comput Aided Mol Des       Date:  1987-04       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.